1. Background
2. Objectives
3. Methods
3.1. Antimicrobial Sensitivity Pattern
3.2. ESBLs Phenotypic Screening
3.3. Detection of bla TEM, bla SHV, and bla CTX-M Genes
| Target Gene | Primer Sequence (5´- 3´) | Amplicon Size (bp) | Conditions | Volume Reactions | Reference |
|---|---|---|---|---|---|
| bla CTX-M | -TTTGCGATGTGCAGTACCAGTAA-; -CGATATCGTTGGTGGTGCCATA- | 590 | 1 cycle: 94°C; 4 min; 35 cycle: 94°C; 45 s; 56°C; 45 s; 72°C; 45 s; 1 cycle: 72°C; 7 min | 10X PCR Buffer: 2.5 μL, 10 mM dNTPs: 0.5 μL, 10 mM MgCl2:0.75 μL, 10 pmol F + R Primer: 1.25 μL, Taq DNA polymerase (5u μL): 0.2 μL, Template DNA: 5 μL; H2O up to 25 μL | (18) |
| bla TEM | -AGTGCTGCCATAACCATGAGTG-; -CTGACTCCCC GTCGTGTAGATA- | 431 | 1 cycle: 95°C; 5 min; 36 cycle: 95°C; 60 s; 54°C;.60 s; 72°C; 60 s; 1 cycle: 72°C; 5 min | 10X PCR Buffer: 2.5 μL, 10 mM dNTPs: 0.5 μl, 10 mM MgCl2: 0.75 μL, 10 pmol F + R Primer: 1.25 μL, Taq DNA polymerase (5u μL): 0.2 μL, Template DNA: 5 μL; H2O up to 25 μL | (19) |
| bla SHV | -GATGAACGCTTTCCCATGATG-; -CGCTGTTATCGCTCATGGTAA- | 214 | 1 cycle: 94°C; 5 min; 38 cycle: 94°C; 60 s; 53°C; 60 s; 72°C; 60 s; 1 cycle: 72°C;.7 min | 10X PCR Buffer: 2.5 μL, 10 mM dNTPs: 0.5 μL, 10 mM MgCl2: 0.75 μL, 10 pmol F + R Primer: 1.25 μL, Taq DNA polymerase (5u μL): 0.2 μL, Template DNA: 5 μL; H2O up to 25 μL | (19) |
3.4. Statistical Analysis
4. Results
| Variables | E. coli (N = 100) | K. pneumoniae (N = 30) |
|---|---|---|
| Gender | 76 (76) | 18 (60) |
| Female | ||
| Male | 24 (24) | 12 (40) |
| Clinical specimen | 84 (84) | 16 (53.47) |
| Urine | ||
| Blood | 12 (12) | 5 (16.6) |
| Sputum | 1 (1) | 5 (16.6) |
| Wound | 3 (3) | (13.3) |
| Sections | 29 (29) | 9 (30) |
| ICU | ||
| Emergency | 38 (38) | 9 (30) |
| Surgery | 8 (8) | 4 (13.3) |
| Internal | 25 (25) | 8 (26.7) |
a Values are expressed as No. (%).
Gel electrophoresis shows the PCR products of bla TEM, bla SHV, and bla CTX-M (A, Lane 1, DNA ladder 100 bp; Lane 2, control positive of bla TEM; Lane 3, control negative of bla TEM; Lanes 4 and 5, clinical isolates carrying bla TEM; B, Lane 1, DNA ladder 100 bp; Lane 2, control positive of bla CTX-M; Lane 3, control negative of bla CTX-M; Lanes 4 - 9, clinical isolates carrying bla CTX-M. C; Lane 1, DNA ladder 100 bp; Lane 2, control positive of bla SHV, Lane 3; control negative of bla SHV; Lanes 4 - 7, clinical isolates carrying bla SHV).
